Contributor content
Presentation
Presentation
High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban
Presentation
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries
Presentation
Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease: a nationwide cohort study
Presentation
Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios
Presentation
Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding
Presentation
